296 related articles for article (PubMed ID: 26654669)
1. Effects of Surgery and Antiplatelet Therapy in Ten-Year Follow-Up from the Registry Study of Research Committee on Moyamoya Disease in Japan.
Yamada S; Oki K; Itoh Y; Kuroda S; Houkin K; Tominaga T; Miyamoto S; Hashimoto N; Suzuki N;
J Stroke Cerebrovasc Dis; 2016 Feb; 25(2):340-9. PubMed ID: 26654669
[TBL] [Abstract][Full Text] [Related]
2. Stroke prevention by direct revascularization for patients with adult-onset moyamoya disease presenting with ischemia.
Kim T; Oh CW; Kwon OK; Hwang G; Kim JE; Kang HS; Cho WS; Bang JS
J Neurosurg; 2016 Jun; 124(6):1788-93. PubMed ID: 26636391
[TBL] [Abstract][Full Text] [Related]
3. Risk profile in extracranial/intracranial bypass surgery--the role of antiplatelet agents, disease pathology, and surgical technique in 168 direct revascularization procedures.
Schubert GA; Biermann P; Weiss C; Seiz M; Vajkoczy P; Schmiedek P; Thomé C
World Neurosurg; 2014 Nov; 82(5):672-7. PubMed ID: 23838364
[TBL] [Abstract][Full Text] [Related]
4. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Takahashi S; Mizuno O; Sakaguchi T; Yamada T; Inuyama L
Adv Ther; 2014 Jan; 31(1):118-29. PubMed ID: 24385407
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of one-stage direct revascularization and medicine therapy for treatment of ischemic moyamoya disease].
Zhao H; You C
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Sep; 23(9):1097-100. PubMed ID: 19817297
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China.
Liu XJ; Zhang D; Wang S; Zhao YL; Teo M; Wang R; Cao Y; Ye X; Kang S; Zhao JZ
J Neurosurg; 2015 Feb; 122(2):392-9. PubMed ID: 25423267
[TBL] [Abstract][Full Text] [Related]
7. Effect of direct arterial bypass on the prevention of future stroke in patients with the hemorrhagic variety of moyamoya disease.
Kawaguchi S; Okuno S; Sakaki T
J Neurosurg; 2000 Sep; 93(3):397-401. PubMed ID: 10969936
[TBL] [Abstract][Full Text] [Related]
8. Moyamoya disease in China: its clinical features and outcomes.
Duan L; Bao XY; Yang WZ; Shi WC; Li DS; Zhang ZS; Zong R; Han C; Zhao F; Feng J
Stroke; 2012 Jan; 43(1):56-60. PubMed ID: 22020027
[TBL] [Abstract][Full Text] [Related]
9. Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization.
Jea A; Smith ER; Robertson R; Scott RM
Pediatrics; 2005 Nov; 116(5):e694-701. PubMed ID: 16263984
[TBL] [Abstract][Full Text] [Related]
10. Long term outcome and predictors of ischemic stroke recurrence in adult moyamoya disease.
Noh HJ; Kim SJ; Kim JS; Hong SC; Kim KH; Jun P; Bang OY; Chung CS; Lee KH; Lee KH; Kim GM
J Neurol Sci; 2015 Dec; 359(1-2):381-8. PubMed ID: 26671146
[TBL] [Abstract][Full Text] [Related]
11. [Experience of 97 patients with moyamoya disease: long-term follow-up at a single center].
Liu XJ; Zhang D; Wang S; Zhao YL; Wang R; Zhao JZ
Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(9):604-7. PubMed ID: 22800948
[TBL] [Abstract][Full Text] [Related]
12. Outcome in adult patients with hemorrhagic moyamoya disease after combined extracranial-intracranial bypass.
Jiang H; Ni W; Xu B; Lei Y; Tian Y; Xu F; Gu Y; Mao Y
J Neurosurg; 2014 Nov; 121(5):1048-55. PubMed ID: 25127415
[TBL] [Abstract][Full Text] [Related]
13. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome.
Smith ER; McClain CD; Heeney M; Scott RM
Neurosurg Focus; 2009 Apr; 26(4):E10. PubMed ID: 19335126
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack.
Depta JP; Fowler J; Novak E; Katzan I; Bakdash S; Kottke-Marchant K; Bhatt DL
Stroke; 2012 Sep; 43(9):2376-81. PubMed ID: 22713488
[TBL] [Abstract][Full Text] [Related]
15. Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan: Results of a Nationwide Survey.
Oki K; Katsumata M; Izawa Y; Takahashi S; Suzuki N; Houkin K;
J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3605-3612. PubMed ID: 30220629
[TBL] [Abstract][Full Text] [Related]
16. Ischemic Stroke in Young Adults with Moyamoya Disease: Prognostic Factors for Stroke Recurrence and Functional Outcome after Revascularization.
Zhao M; Deng X; Gao F; Zhang D; Wang S; Zhang Y; Wang R; Zhao J
World Neurosurg; 2017 Jul; 103():161-167. PubMed ID: 28408257
[TBL] [Abstract][Full Text] [Related]
17. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial.
Al-Shahi Salman R; Minks DP; Mitra D; Rodrigues MA; Bhatnagar P; du Plessis JC; Joshi Y; Dennis MS; Murray GD; Newby DE; Sandercock PAG; Sprigg N; Stephen J; Sudlow CLM; Werring DJ; Whiteley WN; Wardlaw JM; White PM;
Lancet Neurol; 2019 Jul; 18(7):643-652. PubMed ID: 31129065
[TBL] [Abstract][Full Text] [Related]
18. Impact of cortical hemodynamic failure on both subsequent hemorrhagic stroke and effect of bypass surgery in hemorrhagic moyamoya disease: a supplementary analysis of the Japan Adult Moyamoya Trial.
Takahashi JC; Funaki T; Houkin K; Kuroda S; Fujimura M; Tomata Y; Miyamoto S
J Neurosurg; 2020 Mar; 134(3):940-945. PubMed ID: 32168484
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up results in 142 adult patients with moyamoya disease according to management modality.
Lee SB; Kim DS; Huh PW; Yoo DS; Lee TG; Cho KS
Acta Neurochir (Wien); 2012 Jul; 154(7):1179-87. PubMed ID: 22476796
[TBL] [Abstract][Full Text] [Related]
20. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
Griessenauer CJ; Lebensburger JD; Chua MH; Fisher WS; Hilliard L; Bemrich-Stolz CJ; Howard TH; Johnston JM
J Neurosurg Pediatr; 2015 Jul; 16(1):64-73. PubMed ID: 25837886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
